Aurelia Alexandru

机构：Ovidius University, Institutul Oncologic Bucuresti, Spitalul Clinic de Urgenta Sfantul Ioan · ORCID：0009-0009-1420-1034

发表论文 57 篇 · 总被引 9918 次 · h-index 18

代表论文

• Perioperative Nivolumab in Resectable Lung Cancer (2024 · New England Journal of Medicine · 被引 492)
• First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations (2022 · Journal of Thoracic Oncology · 被引 102)
• Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial (2024 · European Journal of Cancer · 被引 83)
• Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1 (2023 · Journal of Thoracic Oncology · 被引 77)
• Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial (2024 · Journal for ImmunoTherapy of Cancer · 被引 63)
• Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. (2024 · Journal of Clinical Oncology · 被引 62)